Research programme: genome editing therapeutics - Editas Medicine

Drug Profile

Research programme: genome editing therapeutics - Editas Medicine

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator Editas Medicine
  • Class Gene therapies
  • Mechanism of Action Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alpha 1-antitrypsin deficiency; Cystic fibrosis; Duchenne muscular dystrophy; Eye disorders; Haematological disorders; Leber congenital amaurosis

Most Recent Events

  • 09 Aug 2016 Editas Medicine and Adverum Biotechnologies collaborate to evaluate genome editing therapeutics with AAV vectors for Eye disorders
  • 28 Jul 2016 Editas Medicine and Fondazione Telethon and Ospedale San Raffaele agree to co-develop genome edited hematopoietic stem cell (HSC)
  • 16 May 2016 Editas Medicine enters into a agreement with Cystic Fibrosis Foundation Therapeutics for the development of genome editing therapeutics for Cystic Fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top